Renin-Angiotensin System Blockers and the COVID-19 Pandemic

Follow the link below to read a fascinating article relating to the current COVID 19 situation. The commentary  concludes that based on current evidence, there is no
reason to abandon RAS blockers in patients receiving this important class of antihypertensive agents because of concerns of either increased risk of contracting SARS-CoV-2 or worsening its course.

 

Renin-Angiotensin System Blockers and the COVID-19 Pandemic

 

 

Get in touch

Our team are on hand to answer any questions you may have.

Not readable? Change text. captcha txt
0